XML 39 R34.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reported Segment Revenues, and Significant Segment Expenses | The following table presents information about reported segment revenues, and significant segment expenses as provided to the CODM.
|  | Three Months Ended September 30, |  |  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 13,129 |  |  | $ | 9,300 |  |  | $ | 36,219 |  |  | $ | 11,564 |
Total revenue |  |  | 13,129 |  |  |  | 9,300 |  |  |  | 36,219 |  |  |  | 11,564 |
Operating costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of product revenue |  |  | 1,088 |  |  |  | 806 |  |  |  | 2,607 |  |  |  | 894 |
Direct, external research and development expenses by program: |  |  |  |  |  |  |  |  |  |  |  |
Pemivibart |  |  | 333 |  |  |  | 4,637 |  |  |  | 2,629 |  |  |  | 27,936 |
VYD2311 |  |  | 265 |  |  |  | 45,045 |  |  |  | 2,778 |  |  |  | 64,175 |
Adintrevimab |  |  | 41 |  |  |  | 128 |  |  |  | 368 |  |  |  | 475 |
Total direct, external research and development expenses by program |  |  | 639 |  |  |  | 49,810 |  |  |  | 5,775 |  |  |  | 92,586 |
Unallocated research and development expenses(1) |  |  | 6,585 |  |  |  | 7,108 |  |  |  | 20,046 |  |  |  | 23,261 |
Other segment items(2) |  |  | 12,767 |  |  |  | 11,021 |  |  |  | 41,717 |  |  |  | 35,739 |
Stock-based compensation |  |  | 3,073 |  |  |  | 2,866 |  |  |  | 9,079 |  |  |  | 16,731 |
Total operating costs and expenses |  |  | 24,152 |  |  |  | 71,611 |  |  |  | 79,224 |  |  |  | 169,211 |
Loss from operations |  |  | (11,023 | ) |  |  | (62,311 | ) |  |  | (43,005 | ) |  |  | (157,647 | )
Other income: |  |  |  |  |  |  |  |  |  |  |  |
Other income, net(3) |  |  | 553 |  |  |  | 1,572 |  |  |  | 1,586 |  |  |  | 6,165 |
Total other income, net |  |  | 553 |  |  |  | 1,572 |  |  |  | 1,586 |  |  |  | 6,165 |
Net loss |  | $ | (10,470 | ) |  | $ | (60,739 | ) |  | $ | (41,419 | ) |  | $ | (151,482 | )
(1) Includes personnel related expenses (excluding research and development stock-based compensation) and external discovery-related and other costs. (2) Includes commercial, general and administrative personnel related costs (excluding stock-based compensation), professional and consulting fees and other costs. Includes interest income of $554 and $1,563 for the three months ended September 30, 2025 and 2024, respectively and interest income of $1,587 and $6,325 for the nine months ended September 30, 2025 and 2024, respectively.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration